Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This multi-institutional study will prospectively collect tumor and constitutional tissue samples from patients with diffuse brainstem glioma and other types of brainstem gliomas either during therapy or at autopsy to perform an extensive analysis of genetic and molecular abnormalities in these tumors.

Further Study Information

Since very little is known about the biology of diffuse brainstem glioma, the goal of this protocol is to undertake a systematic analysis of DNA abnormalities, and of RNA and protein expression in prospectively collected fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.

OBJECTIVES:

• Perform genome-wide analysis of DNA gains and losses and RNA expression in tumor samples and normal tissue from patients with diffuse brain stem glioma.

• Identify regions of genomic gain or loss using either array comparative genomic hybridization or single nucleotide polymorphism arrays.

• Investigate genome-wide expression patterns of RNA derived from tumor samples and normal tissue from these patients via Affymetrix gene expression profiling.

• Validate the results of the genome-wide analysis by conducting further evaluation of candidate genes or by investigating the expression of relevant gene products at the RNA and protein levels.

• Perform analysis of mutations in candidate tumor-suppressor genes and oncogenes (including whole genome sequencing studies) using direct sequence analysis of tumor DNA and confirm the tumor-specific nature of these mutations by analyzing the correspondent constitutional DNA.

• Confirm genomic gains or losses identified by means of fluorescence in situ hybridization (FISH) performed on tissue microarray using non-neoplastic brain tissue from each patient as control when available.

• Explore protein expression patterns identified by immunohistochemistry or western blot and compare them to normal brain stem tissue.

• To obtain a follow-up (questionnaire and/or telephone interview) after autopsy with parent(s), legal guardian(s), or family members of research participants in the United States to assess aspects associated with this procedure, including potential benefits and drawbacks

Eligibility Criteria

Inclusion Criteria

• Patients of any age with clinical and radiologic diagnosis of diffuse brainstem glioma

• Patients with other high-grade gliomas originating in the brainstem

• Patients with focal gliomas (WHO grade I/II) of the brainstem

• Enrollment in the current version of the St. Jude Tissue Bank protocol for patients whose tissue samples were obtained at diagnosis and who received treatment at SJCRH, or correspondent tissue banking consent for patients treated in other institutions if tissue was obtained prior to death (as applicable, depending on the standard of each institution)

Exclusion Criteria

• Patients with any type of infiltrative low-grade (WHO grade II) or high-grade glioma (WHO grade III and IV) originating outside the brainstem

• Patients harboring primary brainstem tumors with other histologic diagnoses (e.g., PNET)

Trial Contact Information

Trial Lead Organizations/Sponsors

St. Jude Children's Research Hospital

Alberto Broniscer

Principal Investigator

Alberto Broniscer, MD		Ph: 866-278-5833
		Email: info@stjude.org

U.S.A.
California
	Palo Alto
		Paul Fisher, MD	Principal Investigator
	Stanford Cancer Center
		Paul Fisher, MD	Ph: 650-725-8630
			Email: pfisher@stanford.edu
Tennessee
	Memphis
		Alberto Broniscer, MD	Principal Investigator
	St. Jude Children's Research Hospital
		Alberto Broniscer, MD	Ph: 866-278-5833
Washington
	Seattle
		Jeffrey R. Geyer, MD	Principal Investigator
	Children's Hospital and Regional Medical Center - Seattle
		Jeffrey R. Geyer, MD	Ph: 206-987-6664

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00899834
Information obtained from ClinicalTrials.gov on April 15, 2012

Back to Top